Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 Vaccines Manufacturing

Time Is Now To Seek US Funding, Financing To Expand Domestic COVID-19 Vaccine Supply Chain

  • Analysis

Executive Summary

BARDA and Development Financing Corp. officials provide insights into window of opportunity for partnering on manufacturing scale-up.

You may also be interested in...



BARDA Expands US Domestic Production Of Single-Use Systems For Vaccine Manufacturing

FlexBiosys wins award; others to follow. New capacity may also benefit manufacture of monoclonal antibodies and cell and gene therapies.

Pandemic Response Strains Global Biopharmaceutical Reactor Capacity

Distress grows as manufacturers wait for suppliers to boost production. One idea: stretch inventories by qualifying single-use bioreactors for reuse.

BARDA To Help Expand Manufacture Of Supplies Needed To Produce COVID-19 Vaccines

Agency requests proposals to boost surge capacity for single-use bags, tubing sets, vials, raw materials, vaccine plants.

Table

View full table

Related Content

In Vivo
Pink Sheet

Topics

Tags:
Coronavirus COVID-19 Vaccines Manufacturing
Latest Headlines

Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings

Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention

Regulatory Flexibility: BrainStorm’s Problematic NurOwn BLA May Be A Bridge Too Far For US FDA

And Then There Were 19: NurOwn Adcomm Loses Temporary Voting Member To Last-Minute Recusal

See All
UsernamePublicRestriction

Register

PS144714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By